Survival of Male Breast Cancer in Fars, South of Iran by Salehi, A et al.
 
 
Iran Red Crescent Med J 2011; 13(2):99-105 ©Iranian Red Crescent Medical Journal 
Survival of Male Breast Cancer in Fars, South of Iran 
 
 
A Salehi
1, H Zeraati
1, K Mohammad
1, M Mahmoudi
1, AR Talei
2, A Ghaderi
3, MH Imanieh
4, 
A Fotouhi
1* 
 
1Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical 
Sciences, Tehran, Iran 
2Department of Surgical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran 
3Department of Immunology, Shiraz Institute for Cancer Research, Shiraz University of Medical Sci-
ences, Shiraz, Iran 
4Gastroenterohepatology Research Center, Department of Pediatric Gastroenterology, Shiraz Uni-
versity of Medical Sciences, Shiraz, Iran 
 
 
Abstract 
 
Background: Although breast cancer in men is uncommon, its incidence rate has an increasing trend. Due to its 
low incidence, there are few studies in this subject and limited information is available. The purpose of this study 
was to investigate clinicopathological characteristics and survival of male breast cancer (MBC) in Fars Province, 
south of Iran. 
 
Methods: The data for this study were obtained from the population based cancer registry of Vice-Chancellor for 
Health Affairs of Shiraz University of Medical Sciences and Shiraz hospitals between January 1, 1989 and Janu-
ary 1, 2008, including 64 patients with MBC. Demographic, clinical and pathological aspects were investigated. 
The Kaplan-Meier method was used for the determination of survival rate and Log Rank test for the comparison. 
The Cox proportional hazards model was used for the multiple analysis. 
 
Results: The patients’ mean age at the time of diagnosis was 60.3 years (SD=12.7). The most frequent age 
group (26.6%) was 51-60 years. The most common symptom (96.8%) was a palpable mass. The majority of 
patients (44.4%) had a symptom duration of less than or equal to 6 months. 56.3% of the patients had a tumor 
size of 2-4.9  cm. Forty six percent of the cases had axillary lymph node involvement. The median survival time 
was  10.0  years  [95%  confidence  interval  (CI):  6.0-14.0].  The  5  year  overall  survival  rate  was  66.0%  (95% 
CI=51.0-81.0%). The median survival time of patients with axillary lymph node involvement was 8.2 years (95% 
CI=6.7-9.6) and for the cases without involvement was 12.0 years (95% CI=8.4-15.2). In addition to axillary 
lymph node involvement, positive family history in contrast to negative family history and left tumors in compari-
son with right tumors were poorer prognostic factors in univariate analysis respectively (p=0.006, p=0.031). In 
multiple  analysis,  axillary  lymph  node  involvement  was  an  independent  predictor  of  poorer  survival  (Hazard 
ratio=1.6, 95% CI=1.1-6.4, p=0.030) and the other variables did not have a significant effect. 
 
Conclusion: The mean age of MBC in this series is lower than that in western countries. It is compatible to the 
mean age of female breast cancer which is approximately one decade less than that in developed countries. The 
survival rate of MBC is relatively lower than that in western countries. Axillary lymph node involvement is an 
important prognostic factor in the survival of MBC. Multicenter population based studies with greater number of 
patients are required for better estimation of different aspects of MBC in Iran. 
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Introduction 
 
According to Somerville (1952), the first reported case 
of male breast cancer (MBC) appeared in medical pub-
lication of Francisus Arcaeus (1493-1573).
1 Although 
breast cancer in men is uncommon and accounts for 
approximately 1% of all cases of malignancy in men, 
its incidence rate has had an increasing trend and has 
accelerated  annually  by  0.9%  in  the  USA  between 
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1975-2006, while the incidence rate of breast cancer in 
women has decreased by 2% per year between 1999-
2006.
2  The  reasons  for  the  increase  are  unknown  
and  are  not  attributable  to  increased  detection.
3  
This increasing incidence is also present in other na-
tions.
4 Death rate from MBC has remained essentially 
constant since 1975 while it has decreased in women 
by 1.9% annually between 1998-2006.
3 MBC cases 
had been 0.7% of all breast cancer cases and death of 
men due to breast cancer had been 1% of all breast 
cancer deaths in 2002 but these proportions have in-
creased to 1.08% and 1.1% respectively in 2008.
4-6 
There is a geographical variation in MBC occur-
rence. For example, MBC comprises 1% of all breast 
cancers in Europe and 0.4-0.6% in Korea.
3,7 In con-
trast,  6%  of  all  breast  cancer  diagnoses  in  men  in 
Tanzania and even higher percentages are reported in 
some  other  countries  in  central  Africa.
8,9  MBC  ac-
counts for 0.65% of all cases of malignancy in men in 
Iran. There are 6674 incident cases of breast cancer 
diagnosed  in  Iran  in  2007  of  whom  3.26%  were 
men.
10  In  a  hospital-based  cancer  registry  in  Fars 
Province, southern Iran, the crude incidence rate and 
ASR for MBC were reported 0.22 and 0.34 respec-
tively.  These  figures  for  females  were  11.58  and 
18.06 respectively.
11 
Significant differences in the biological and clini-
copathological  characteristics  have  been  described 
between male and female breast cancer.
4,12 Because of 
its low incidence, MBC has not been studied as ex-
tensively as female breast cancer. Appropriate man-
agement guidelines for MBC have not yet been clear-
ly  established,  and  limited  information  is  available 
concerning the epidemiology, treatment, and progno-
sis of this disease. Therefore, the treatment guidelines 
have been extrapolated from the data based on female 
breast cancer.
13,14 It follows that the study of MBC 
becomes more important every day. In this study, we 
investigated  clinicopathological  characteristics  and 
survival of MBC in Fars, southern Iran. 
 
 
Materials and Methods 
 
The data for this study were obtained from the popu-
lation  based  cancer  registry  of  Vice-Chancellor  for 
Health Affairs of Shiraz University of Medical Sci-
ences and Shiraz hospitals between January 1, 1989 
and January 1, 2008, including 64 patients with MBC. 
Their medical records were reviewed carefully. The 
data bank of Pathology Department was used to com-
plete the information. The variables studied were de-
mographic data including the patient age at diagnosis, 
job, marital status, and residence, clinical data includ-
ing history of benign tumor, history of tobacco and 
alcohol  use,  type  and  duration  of  symptoms,  and 
pathological  data  including  tumor  size,  histological 
type,  axillary  lymph  node  involvement,  laterality, 
chest wall invasion, staging and grading. The survival 
data  were  obtained  from  Death  Registry  of  Vice-
Chancellor for Health Affairs of Shiraz University of 
Medical Sciences and telephone contacts were made 
to  complete  the  information.  The  tumor  stage  was 
based on the 6th American Joint Committee on Can-
cer (AJCC)  criteria. The grading  followed  Notting-
ham modification of the Bloom- Richardson System. 
SPSS (Chicago, IL, USA, Version 15) was used for 
statistical analysis. We used Kaplan-Meier method to 
determine  the  survival  rate  and  Log  Rank  test  for 
comparison. The Cox proportional hazards model was 
used for the multiple analysis. Right censor was ap-
plied from the final day to those who survived the 
study period, and other certain deaths for those who 
were lost to follow up. P value less than 5% was con-
sidered significant. 
 
 
Results 
 
Patients' mean age at time of diagnosis was 60.3 years 
(12.7). Minimum and maximum ages of cases were 
32 and 87 years. Forty five patients (70.0%) were di-
agnosed after the age of 50 years. The most frequent 
age group (26.6%) was 51-60 years. General charac-
teristics of the patients are presented in Table 1. 
The most common symptom was a palpable mass 
(96.8%). Ten patients (15.6%) had nipple discharge. 
Two cases had bilateral breast cancer. The majority of 
patients (44.4%) had a symptom duration of less than 
or equal to 6 months. The clinical characteristics of 
the patients are summarized in Table 2. Twenty seven 
patients (56.3%) had a tumor size of 2-4.9 cm. Forty 
six percent of the cases had axillary lymph node in-
volvement.  The  pathologic  characteristics  are  pre-
sented in Table 3. 
Survival data for 56 patients (87%) were available. 
There were 19 deaths reported among the patients and 
37 men were alive until the end of the study. Median 
follow-up time, from first pathological diagnosis until 
the time of death or the end of study, was 60 months. 
The median survival time was 10 years (95%CI: 6-
14). The 3, 5 and 10 year overall survival rates were Survival of male breast cancer 
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83% (95% CI=72-94%), 66% (95% CI=51-81%) and 
45%  (95%  CI=24-66%),  respectively.  In  univariate 
analysis;  axillary  lymph  node  involvement,  family 
history of breast cancer and laterality were predictor 
variables with significant effect on survival rate. The 
median survival time of patients with axillary lymph 
node  involvement  was  8.2  years  (95%  CI=6.7-9.6) 
and for the cases without involvement was 12.0 years 
(95%  CI=8.4-15.2,  p=0.007).  Patients  with  positive 
family history had poorer survival (p=0.006). Surviv-
al rates of patients with right breast cancer were better 
than the survival rates of those with cancer on the left 
side (p=0.031). The median survival time according 
to the clinicopathological characteristics are summa-
rized in Table 4. In multiple Cox regression, axillary 
lymph node involvement was an independent predic-
tor of poorer survival (Hazard ratio=1.6, 95% CI=1.1-
6.4) and the other variables had not significant effect. 
 
 
Discussion 
 
This  study  has  shown  that  patients'  mean  age  and 
survival rate of MBC in Iran is lower than western 
countries.  The  mean  age  at  time  of  diagnosis  in 
breast  cancer  is  reported  to  be  approximately  63 
years in women and 68 years in men in North Amer-
ica and Western Europe.
15-17 According to two stud-
ies in Turkey, the mean age of MBC has been found 
to be 58 and 60 years.
18,19 In Japan and Korea, 62.5 
and  58  years  are  reported  for  the  mean  age  of 
MBC.
8,20 The mean age for the cases in our study 
was 60.3 years which is lower than that in western 
countries  and  similar  to  Asian  study  reports.  It 
matches the mean age of female breast cancer in Iran 
which is approximately one decade less than that in 
developed  countries.
21  As  with  women,  the  most 
common symptom of breast cancer is painless lump, 
which alone or with other problems arises in 50-97% 
of  cases.
22,23  In  this  study,  96.8%  of  patients  had 
breast lump. 
Since male breast tissue is rudimentary, it does not 
usually  differentiate  and  undergo  lobular  formation 
unless exposed to increased concentrations of endog-
enous or exogenous estrogen. Thus the predominant 
histological type of disease is invasive ductal, which 
makes  up  more  than  90%  of  all  male  breast  tu-
mors.
15,24 Yoney et al. have reported 94.9% invasive 
Table 1: General characteristics of male breast cancer patients 
Characteristics  Patients (n=64)  % 
Age at Diagnosis (year)  64
a  100 
<40  5  7.8 
41-50  14  21.9 
51-60  17  26.6 
61-70  13  20.3 
71-80  12  18.7 
>80  3  4.7 
Residence  60  94.0 
Fars  50  83.0 
Other Provinces  10  17.0 
Marital status  43  67.0 
Married  42  98.0 
Single  1  2.0 
History of Benign tumor  61  95.0 
Negative  60  98.0 
Positive  1  2.0 
History of Alcohol Use  58  90.0 
Negative  42  72.4 
Positive  16  27.6 
History of Tobacco Use  42  65.6 
No tobacco use  20  47.6 
Current tobacco use  16  38.1 
Past tobacco use  6  14.3 
aTotal number available of the 64 subjects  
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ductal  carcinoma  in  their  study.
18  The  histological 
type of all tumors of the patients in our study was in-
vasive  ductal  carcinoma.  In  large  reported  series, 
most of the cases (54-58%) were grade II.
15 In our 
study, 54.3% of the patients were grade II.  
The treatment strategy for breast cancer in men 
is  the  same  as  that  in  women  and  the  primary 
treatment is mastectomy with axillary dissection.
25-
27 In the past, radical mastectomy was preferred and 
the rationale for this was the localized lesion being 
close to the pectoralis major muscle and the tumor 
in a more advanced stage in men compared to that 
in women at the time of diagnosis.
28 Recent studies 
are in favor of modified radical or simple mastec-
tomy  combined  with  radiation  therapy.
15,29  There 
seems  to  be  no  prominent  difference  in  survival 
between  these  methods.
28  In  our  study,  modified 
radical mastectomy was done for 55 cases (85.9%), 
and radical mastectomy for 5 patients (7.8%). In-
formation on operation done on four of the patients 
was not available.  
Some studies suggested that breast cancer has a 
worse prognosis in men than in women, but if age-
matched and stage- matched breast cancer are com-
pared, there is no difference between the sexes.
30 Five 
and 10 years overall survival of breast cancer in men 
is reported as 63-85.5% and 41-76% in different stud-
ies.
8,18,31 In Fars Province Hospital-based Cancer Reg-
istry,  five-year  overall  survival  was  58%  (95% 
CI=53%–62%) in females.
32 In our study, 5 and 10 
years overall survival rates were 66% and 45%, re-
spectively.  Different  results  have  been  reported  re-
Table 2: Clinical characteristics of male breast cancer patients 
Characteristics  Patients (n=64)  % 
Mass  64  100.0 
Yes   62  96.8 
No  2  3.2 
Nipple Discharge   64  100.0 
Yes   10  15.6 
No  54  84.4 
Nipple Ulceration  64  100.0 
Yes  8  12.5 
No  56  87.5 
Nipple Retraction  64  100.0 
Yes  7  11.0 
No  57  89.0 
Skin Fixation  64  100.0 
Yes  10  15.7 
No  54  84.3 
Skin Ulceration  64  100.0 
Yes  4  6.3 
No  60  93.7 
Skin Redness  64  100.0 
Yes  7  11.0 
No  57  89.0 
Palpable Axillary Lymph Node  64  100.0 
Yes  4  6.0 
No  60  94.0 
Arm Swelling  64  100.0 
Yes  0  0.0 
No  64  100.0 
Duration of Symptoms (month)  45  70.3 
Symptom≤6  20  44.4 
6< Symptom ≤12  14  31.2 
12< Symptom ≤24  6  13.3 
24< Symptom  5  11.1 
 Survival of male breast cancer 
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garding tumor size and survival of MBC. It has been 
argued that the large size of tumors can be considered 
a poor prognostic factor for survival in MBC.
15 A few 
studies, of course, have found no relationship between 
tumor size and the prognosis.
18 In our study, there was 
no  significant  correlation  between  tumor  size  and  
survival. This could be due to the small number of pa-
tients or the effect of other prognostic factors. 
The  axillary  lymph  node  involvement  in  male 
breast cancer is reported approximately 55% in vari-
ous studies and is considered a poor prognostic factor 
in most of them.
20,29,30 In our study, 46% of the pa-
tients had axillary lymph node involvement and their 
5 years survival rate was 45% which is significantly 
lower  than  the  68%  survival  rate  in  cases  without 
lymph node involvement. 
To our knowledge, this is the first study to eval-
uate survival of MBC in Iran and it may be a basis 
for further necessary studies regarding this malig-
nancy  in  our  country.  Limitations  include  retro-
spective  design  of  the  study,  the  lack  of  enough 
information  regarding  estrogen  and  progesterone 
receptors, inadequate number of patients and lack 
of  detailed  information  due  to  radiotherapy  and 
chemotherapy. 
In conclusion, the mean age of MBC in this se-
ries  is  lower  than  that  in  western  countries.  It  is 
compatible to the mean age of female breast cancer 
which is approximately one decade less than that in 
developed countries. The survival rate of MBC is 
relatively  lower  than  that  in  western  countries. 
There are few studies on MBC due to its rarity and 
information about different aspects of the disease is 
not enough, especially in the developing countries 
and  further  investigations  are  required,  especially 
during multicenter studies with a greater number of 
patients. 
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Table 3: Pathologic characteristics of male breast cancer patients 
Characteristics  Patients (n=64)  % 
Tumor Size  48  75.0 
<2  9  18.7 
2-4.9  27  56.3 
>4.9  12  25.0 
Stage  53  82.8 
0  1  1.9 
I  5  9.4 
II  38  71.7 
III  6  11.4 
IV  3  5.6 
Laterality  64  100.0 
Left  31  48.4 
Right  31  48.4 
Bilateral  2  3.2 
Chest wall Invasion  55  85.9 
Negative  49  89.1 
Positive  6  10.9 
Axillary LymphNode Involvement   59  92.2 
Negative   32  54.2 
Positive  27  45.8 
Histological  Grade  46  71.8 
I  19  41.3 
II, III  27  58.7 
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